

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

Batch 35

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

Consultees noted during consultation that people with limited mobility and those who use dosette boxes may benefit from the technology, and that consideration should be given to the suitability of the technology in intravenous drug users, pregnancy and breast feeding, renal dysfunction, liver dysfunction, thrombolysis and people with a history of bleeding. Attendees at the scoping workshop noted that apixaban is contraindicated in many of these circumstances.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The potential issues highlighted during scoping consultation were not related to equalities and do not need to be addressed by the Committee as such.

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): ...Janet Robertson...

Date: 01 July 2014